CRESTONE is a multicenter open-label, phase 2 trial of seribantumab in patients with NRG1 gene fusion-positive, advanced solid tumours. The Australian patient subset, known as MoST CRESTONE, will be identified through the MoST program.
To assess the clinical activity of seribantumab in patients with NRG1 fusion positive locally advanced or metastatic solid tumours.
Elevation Oncology Inc.
Adults with recurrent, locally advanced or metastatic solid tumours which harbour the NRG1 gene fusion and have had received prior standard treatment.